The Latest Breaking News from Medical – Pharmaceuticals

Pharma company Rigel’s (RIGL) REZLIDHIA recently achieved the U.S. Food and Drug Administration’s approval for treating relapsed or refractory acute myeloid leukemia, helping the stock to soar. RIGL shares have gained more than 30% over the past month. Given the industry tailwinds, RIGL might be the ideal stock to buy…

Pfizer (PFE) has been a COVID beneficiary and is expected to continue to gain from its vaccines as the pandemic war is yet to be over. Moreover, PFE offers a more than 3% dividend. Thus, investors might consider buying this quality stock which seems well-positioned to weather any recession. Keep…

Despite economic uncertainties, leading pharma company Bristol-Myers Squibb (BMY) beat street estimates in the fiscal third quarter with solid financials. However, given the current market turmoil, is it too late to get on the upward move in this stock? Continue reading to find out.

Healthcare company Merck & Co. (MRK) is set to acquire Imago BioSciences (IMGO) for more than $1 billion. The stock has gained more than 40% this year. However, given the macroeconomic headwinds, would it be wise to buy the stock now? Read on to find out….

Biopharmaceutical major Bristol-Myers Squibb Company (BMY) beat the consensus earnings and revenue estimates in the third quarter. Given its strong product pipeline, strategic acquisitions, discounted valuation, high profitability, strong financials, and attractive dividends, investors could buy the stock now. Read more….

Biopharma giant AbbVie (ABBV) is well-placed to gain from its drug pipeline, recent drug approvals, and strategic acquisitions. Given its strong fundamentals, discounted valuation, high profitability, reliable dividends, and favorable analyst estimates, investing in this stock could help you retire earlier. Read more.

Leading healthcare company Johnson & Johnson (JNJ) has been able to navigate the volatile market conditions due to the defensive nature of its business and solid fundamentals. Moreover, the company has an impressive history of increasing its dividends. Given JNJ’s robust financials, high profitability, and consistent dividend payouts, we think…

The healthcare industry tends to withstand macroeconomic pressure better than other industries due to the almost inelastic demand for medical products and services. With a recession expected next year, investors could look to capitalize on the defensive characteristics and long-term prospects of the industry by investing in quality medical stocks…

The healthcare industry tends to withstand challenging macro conditions relatively well, as it enjoys inelastic demand for its products and services. And given the solid long-term prospects of the industry, it could be wise to load up fundamentally sound medical stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck (MRK)…

Merck & Co.’s (MRK) third-quarter financials surpassed Wall Street’s expectations. The stock is trading near its 52-week high of $101.50, and its momentum is expected to continue, considering its strong fundamentals. Given the company’s solid growth, reliable dividend payments, and the resilience of its sector against the expected economic slowdown,…

Though the U.S. economy bounced back after shrinking in the first half of the year, falling consumer spending and the rate hikes to tame high inflation might lead the economy into a recession. Hence, investors looking for passive income could invest in fundamentally sound dividend-paying stocks Pfizer (PFE), Sanofi (SNY),…